The utility of laboratory testing for pediatric patients undergoing isotretinoin treatment

Pediatr Dermatol. 2022 Sep;39(5):731-733. doi: 10.1111/pde.15045. Epub 2022 Jun 11.

Abstract

Isotretinoin, the most effective treatment for severe cystic acne, involves laboratory monitoring. In this retrospective case series of 130 pediatric patients taking isotretinoin, there were significant increases in cholesterol (143.9 mg/dl to 155.3 mg/dl), triglycerides (81.8 mg/dl to 115.2 mg/dl), and low-density lipoprotein (82.0 mg/dl to 98.1 mg/dl), and a decrease in high-density lipoprotein (50.0 mg/dl to 44.7 mg/dl) from baseline to follow-up (p < .05); there were no significant changes in liver enzymes. None of the patients had clinical sequelae (triglyceride-induced pancreatitis, retinoid-induced hepatotoxicity) related to their abnormal lab values. These findings question the utility of laboratory monitoring for prevention of severe clinical sequelae in pediatric patients, and suggest testing based on individualized risk factors may be more appropriate.

Keywords: acne; dermatology; hepatotoxicity; isotretinoin; laboratory; liver enzymes; pancreatitis; pediatrics; triglycerides.

MeSH terms

  • Acne Vulgaris* / drug therapy
  • Child
  • Cholesterol / therapeutic use
  • Humans
  • Isotretinoin* / adverse effects
  • Lipoproteins, HDL / therapeutic use
  • Lipoproteins, LDL / therapeutic use
  • Retrospective Studies
  • Triglycerides / therapeutic use

Substances

  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Triglycerides
  • Cholesterol
  • Isotretinoin